Promising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett Syndrome
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
FierceBiotech2d
Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
BioSpace8d
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
Mitchell Kapoor Recommends Buy for Neurogene Due to Strong NGN-401 Low-Dose Safety and Potential Upside
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
BioPharma Dive5d
Neurogene hits a setback in the clinic, days after fundraise
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
pharmaphorum8d
Neurogene shares fall on Rett syndrome gene therapy data
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
bovnews8d
Neurogene’s (NGNE) Surprising Setback: What’s Behind the Stock Drop?
When looking at Neurogene’s stock performance year-to-date, it’s hard to ignore the impressive +269.09% increase. However, this recent downturn suggests that the market is responding to something ...
Neurogene: Interesting CNS Disease Company, Data Coming Soon
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...